This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase I/Expansion Study of Dasatinib (Gem/Dsat)

This study has been terminated.
(Low accrual, unable to meet endpoint in timely manner)
Bristol-Myers Squibb
Information provided by (Responsible Party):
Duke University Identifier:
First received: December 26, 2007
Last updated: September 4, 2015
Last verified: November 2012

The purpose of this study is to find the highest dose of the drugs gemcitabine and dasatinib that can be given for the treatment of pancreatic cancer. Gemcitabine (also called Gemzar™)is a drug that is given intravenously. Dasatinib (also called Sprycel™) is a tablet and will be taken by mouth.

Gemcitabine is approved by the Food and Drug Administration (FDA) for the treatment of advanced breast, lung and pancreatic cancer. Dasatinib is approved by the FDA for the treatment of chronic myeloid leukemia (CML), acute lymphoblastic leukemia or for patients that are resistant to imatinib mesylate (Gleevec™ ).

This study will try to find the highest doses of these drugs that can be tolerated when taken in combination. The study will also look at how the drugs work in the body, and will see if there is any effect on pancreatic cancer.

Condition Intervention Phase
Refractory Solid Tumors Pancreatic Adenocarcinoma Drug: gemcitabine Drug: dasatinib Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • To determine the MTD/Recommended Phase II Dose (RPTD) of gemcitabine plus dasatinib once daily and twice daily dosing in patients with advanced solid tumors [ Time Frame: Phase I portion of the study ]

Secondary Outcome Measures:
  • To describe any dose limiting toxicities for these regimens [ Time Frame: Every 28 days or as clinically indicated ]
  • To describe and non-dose limiting toxicities for these regimens [ Time Frame: Every 28 days or as clinically indicated ]
  • To preliminarily describe markers of efficacy for gemcitabine plus dasatinib in patients with previously untreated metastatic pancreatic cancer: response rate, progression free survival, overall survival. [ Time Frame: Every 8 weeks ]
  • To preliminarily describe changes in blood and urine based biomarkers,at baseline compared to first restaging and at progression, for patients with previously untreated metastatic pancreatic cancer treated on the expanded cohorts at the MTD/RPTD. [ Time Frame: baseline, first restaging, progression ]

Enrollment: 30
Study Start Date: April 2007
Study Completion Date: May 2012
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A Drug: gemcitabine
1000mg/m2, Days 1, 8, 15
Other Name: Gemzar
Drug: dasatinib
50mg, PO, QD
Other Name: Sprycel
Active Comparator: B Drug: gemcitabine
1000mg/m2, days 1, 8, 15
Other Name: Gemzar
Drug: dasatinib
50mg, PO, BID
Other Name: Sprycel

Detailed Description:

This open-label, multicenter, non-randomized phase I trial of gemcitabine plus once and twice daily dasatinib is designed to assess the safety, tolerability, maximum tolerated dose/recommended phase II dose, and preliminary efficacy of this combination in adult patients with advanced solid tumors and with previously untreated metastatic pancreatic cancer. Patients will be accrued at Duke University Medical Center, the Duke Oncology Network, the University of North Carolina at Chapel Hill and Wake Forest Baptist Medical Center

Patients will be accrued to either of the gemcitabine/dasatinib arms in alternating sequential order. In the case where there is an open slot on a particular arm but not the alternative, the enrolled patient will be assigned to that open slot. For example, at the start of the trial, patient #1 will be treated on the gemcitabine with dasatinib twice daily dosing arm, patient #2 on the gemcitabine with dasatinib once daily dosing arm, patient #3 on the gemcitabine with dasatinib twice daily dosing arm, and so on. However, if, due to cohort expansion there is a slot available on one treatment arm but not the other, the patient will be accrued to the open slot.

Additionally, if one arm is held, delayed, or not pursued, accrual to the alternate arm may continue. Patients and their treating physicians will not be able to choose on their own which treatment arm that patient will be assigned to. This enrollment procedure will be the procedure for the entire trial.

For the dose escalation portion of the trial, patients will only be accrued at Duke University Medical Center. For the expanded cohort portion of patients with previously untreated metastatic pancreatic cancer treated at the recommended phase II dose of each arm, patients may be accrued at Duke University Medical Center,and the sites listed above.

NOTE: The first stage closed as of December 2008. Subjects will only be enrolled into the second stage of the this study.

  • Toxicity will be assessed every visit, and as clinically indicated.
  • Dose limiting toxicities will be assessed during cycle 1.
  • Efficacy will be assessed every 2 cycles, and as clinically indicated.
  • Plasma biomarkers will be assessed at baseline and at every restaging.
  • Tissue based biomarkers (tumor and granulation tissue) will be assessed in up to 15 patients treated at Duke only. Tissue biopsy sets (a 4mm "stimulus" biopsy and a 5mm "granulation" tissue biopsy, both in the same location) will also be done both pre-treatment and on-treatment. Pre-treatment biopsies will be done on days -7 and 1, respectively. On-treatment biopsies will be done on days 1 and 8, respectively.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Eligibility Criteria Specific for Dose Escalation Phase

  • Patients must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard therapy would include gemcitabine or for which standard curative or palliative measures do not exist or are no longer effective.
  • Patients must not have had radiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within the 28 days prior to study day 1.

Eligibly Criteria Specific for Expansion Phase at Recommended Phase II Dose

  • Histologically or cytologically documented adenocarcinoma of the pancreas.
  • Metastatic pancreatic cancer as documented by radiologic study or surgical evidence of metastatic disease.
  • No prior chemotherapy for metastatic pancreatic disease. Patients may have received a radiosensiting dose of 5-fluorouracil or capecitabine or other agents used as radiosensitizers with concurrent radiation therapy.
  • Last dose of adjuvant chemotherapy must be at least 4 weeks prior to day 1 of the study drug treatment
  • Prior radiation therapy is allowed. prior to day 1 of the study drug treatment. At least 4 weeks must have elapsed to baseline or grade 1.
  • No prior treatment with gemcitabine or dasatinib in the adjuvant or metastatic setting.
  • Prior gemcitabine only allowed if the gemcitabine was administered in the adjuvant setting and > 6 months has elapsed between diagnosis of metastatic disease and last gemcitabine treatment.
  • No history for other carcinomas within the last five years, except cured non-melanoma skin cancer, curatively treated in-situ cervical cancer, or localized prostate cancer with a current PSA of <1.0 mg/dL on 2 successive evaluations, at least 3 months apart, with the most recent evaluation no more than 4 weeks prior to day 1 of the study drug treatment. .

Eligibility Criteria for All Subjects

  • Age >18 years.
  • Karnofsky performance status >70%.
  • Life expectancy of at least 3 months.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Must meet lab requirements as defined in the protocol
  • Patients should be capable of taking oral medications for prolonged compliance.
  • Sexually active women of childbearing potential must use an effective method of birth control.
  • All WOCBP MUST have a negative pregnancy test within 7 days prior to first receiving investigational product.
  • Pregnant and/or lactating women will be excluded from this study.

Exclusion Criteria:

  • Patients who have had radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for cancer within 28 days prior to day 1 of the study drug treatment. Patients receiving hormonal therapy for metastatic prostate or breast cancer may continue hormonal therapy.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of the study drug treatment
  • Core biopsy or other minor surgical procedure excluding study-related procedures or placement of a vascular access device within 7 days prior to expected start of treatment.
  • Patients who have received any other investigational agents within the 28 days prior to day 1 of the study drug treatment.
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption
  • History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 6 months prior to day 1 of the study drug treatment.
  • History of stroke or transient ischemic attack within 6 months prior to day of the study drug treatment.
  • Uncontrolled congestive heart failure defined as New York Heart Association (NYHA) class II or greater
  • Known cardiomyopathy with decreased ejection fraction (less than institutional normal limits)
  • Diagnosed or congenital long QT syndrome
  • Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
  • Prolonged QTc interval on pre-study electrocardiogram (> 450 msec)
  • Patients with a history of significant bleeding episodes (e.g., hemoptysis, upper or lower GI bleeding) within the previous 6 months of day 1 of the study drug treatment
  • Evidence of bleeding diathesis or coagulopathy. Patients on therapeutic anticoagulation may be enrolled provided that they have been clinically stable on anti-coagulation for at least 2 weeks prior to day 1 of the study drug treatment
  • History of significant bleeding disorder unrelated to cancer
  • Medications that inhibit platelet function
  • Fluid retention (i.e. pleural effusion, ascites, edema) grade > 2.
  • A known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment.
  • Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes
  • Patients actively taking inhibitors or inducers of CYP3A4
  • Patients actively taking proton pump inhibitors or H2 antagonists
  • Other concurrent severe and/or poorly controlled medical condition that could compromise safety of treatment
  • Any psychiatric illness/social situations that would limit safety or compliance with study requirements or may interfere with the interpretation of the results.
  • Patients unwilling to or unable to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00598091

United States, North Carolina
UNC Lineberger, Comprehensive Cancer Center
Chapel Hill, North Carolina, United States, 27599
Duke University Medical Center
Durham, North Carolina, United States, 27710
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Sponsors and Collaborators
Duke University
Bristol-Myers Squibb
Principal Investigator: Hope C Uronis, MD Duke University
  More Information

Responsible Party: Duke University Identifier: NCT00598091     History of Changes
Other Study ID Numbers: Pro00012976
9335 ( Other Identifier: Duke legacy protocol number )
Study First Received: December 26, 2007
Last Updated: September 4, 2015

Keywords provided by Duke University:
Solid Tumors
Phase I
Expanded Cohort
Pancreatic Cancer

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors processed this record on September 21, 2017